OUR STORY

We have expanded the programme for 2017 up to 2 focused tracks over 2 days: a new track on ‘Physician Education, Uptake & Market Access strategies’ and one exploring
‘Development, Manufacturing & harmacovigilance’.
 
Over 60 biosimilar experts will participate on the programme and we’ll be hosting over 300 biosimilar attendees from pharma, biotech, clinicians and healthcare.
 
Collocated with the 13th annual European Antibody Congress and World Immunotherapy
Congress bringing together over 200 speakers and 700 attendees across 3 events over 3 days 2017 will be the best year yet!
 

OUR STORY


2016 was our biggest event to date and it was a real inflection point for the industry.

After several approvals in the US, the Biosimilar Industry is now finally ready to fulfil its promise and become a multi-billion-dollar business providing real benefits to healthcare.

On the back of these approvals it is becoming a far more crowded and competitive landscape but getting a biosimilar to the patient still presents a number of challenges that the World Biosimilar Congress 2017 will look to address. Across the two days, industry and thought-leading speakers from across the globe will come together to network and discuss the key issues on biosimilar drug
development, commercialisation, market access and healthcare uptake.

world biosimilar congress panel discussion

networking at the world biosimilar congress

sponsor delegate interaction at the world biosimilar congress

Key topics will include:

Track 1: Market access strategies, opportunities and commercial challenges 
  • Updates on biosimilar and biobetter regulatory guidelines
  • Streamlining approval and access for follow-on biologics
  • Opportunities and challenges in bringing future  biosimilars to market
  • Emerging markets and the establishment of biosimilar products
  • Technology transfer strategies for market access
  • Successful biosimilar product case studies from benchtop to market
 
Track 2: Biosimilar and Biobetter development 
  • Biosimilar and biobetter development and clinical case studies
  • Designing and conducting global clinical trials
  • Designing clinical models and using data to effectively demonstrate biosimilarity
  • Opportunities in biobetters development
  • The latest on demonstrating interchangeability
  • Approaches to harmonizing immunogenicity testing
  • Novel techniques and technologies for characterisation, assay development and extrapolation
  • *New* Pharmacovigilence (side effects) and innovative clinical trials  

 

DOWNLOAD PROSPECTUS

 

Get involved

To sponsor or exhibit contact Derek Cavanagh
on +44 (0) 207 0921 297 or email  derek.cavanagh@terrapinn.com